| Literature DB >> 35309259 |
Shabnam Ghahremanian1, Mohammad Mehdi Rashidi1,2, Kimai Raeisi3, Davood Toghraie4.
Abstract
Since the commencement of the novel Coronavirus, the disease has quickly turned into a worldwide crisis so that there has been growing attention in discovering possible hit compounds for tackling this pandemic. Discovering standard treatment strategies is a serious challenge because little information is available about this emerged infectious virus. Regarding the high impact of time, applying computational procedures to choose promising drugs from a catalog of licensed medications provides a precious chance for combat against the life-threatening disorder of COVID-19. Molecular dynamics (MD) simulation is a promising approach for assessing the binding affinity of ligand-receptor as well as observing the conformational trajectory of docked complexes over time. Given that many computational studies are performed using MD along with the molecular docking on various candidates as antiviral inhibitors of COVID-19 protease, there is a demand to conduct a comprehensive review of the most important studies to reveal and compare the potential introduced agents that this study covers this defect. In this context, the present review intends to prepare an overview of these studies by considering RMSD, RMSF, radius of gyration, binding free energy, and Solvent-Accessible Surface Area (SASA) as effective parameters for evaluation. The outcomes will offer a road map for adjusting antiviral inhibitors, which can facilitate the selection and development of drug candidates for use in the medical therapy. Finally, the molecular modeling approaches rendered by this study may be valuable for future computational studies.Entities:
Keywords: COVID-19; Coronavirus main protease; Drug discovery; MD simulations; SARS‐CoV‐2
Year: 2022 PMID: 35309259 PMCID: PMC8916543 DOI: 10.1016/j.molliq.2022.118901
Source DB: PubMed Journal: J Mol Liq ISSN: 0167-7322 Impact factor: 6.633
Findings of studies included in the review.
| Reference | Target | Candidate drugs | High score lead |
|---|---|---|---|
| Main protease of SARS-CoV-2 | Darunavir, niclosamide, interferon alpha, lopinavir, ribavirin, ritonavir, umifenovir, hydroxychloroquine, ivermectin and remdesivir | Remdesivir | |
| COVID-19 main protease (Mpro) | Dextromethorphan, Prednisolone, and Dexamethasone | Simultaneous complex with combined of Dexamethasone, Prednisolone, Dextromethorphan (6LU7-D1-P-D2) | |
| Main protease of SARS-CoV-2 (Mpro) | Peptide-like N3-ILP | 54,035,018 | |
| SARS-CoV-2 N7-MTase | Guanine-N7 methyltransferase: | All five TCM components | |
| Mpro | Leupeptin Hemisulphate, Pepstatin A, Nelfinavir, Birinapant, Lypression Octreotide | Nelfinavir and Birinapant | |
| 3CLpro | MolPort-002-530-156, MolPort-002-701-723, MolPort-000-410-348, MolPort-027-852-450, MolPort-039-338-091 | MolPort-000-410-348 | |
| Mpro | AG- 690/11060013 AG-690/11203374-1 | AG-690/11203374-1 AG-690/11203374-2 | |
| Mpro | Sapanisertib, ornidazole, napabucasin, lenalidomide, daniquidone | Daniquidone | |
| SARS-CoV-2 glycoprotein RBD | Cefsulodin, cromoglycate, nafamostat, nilotinib, penfuridol, radotinib | Cefsulodin and nilotinib | |
| RdRp | For Mpro: Mulberroside E Darunavir | Mulberroside E Emblicanin A | |
| 3CLpro | Asinex Focused Covalent library (AFCL): | Cmp 78 | |
| Main protease of the SARS-CoV-2 | ZINC20601870 ZINC00793735 | ZINC00793735 | |
| Spike glycoprotein | Phytochemicals | All investigated compounds | |
| 3CLpro | HIV-1 proteinase inhibitors of lopinavir and ritonavir | Lopinavir and ritonavir | |
| Mpro | HIV protease inhibitors: | Lopinavir and Ritonavir |
Fig. 1Average value of RMSD of high score agents corresponding to the SARS-CoV-2 main protease [34], [35], [37], [44], [41].
Fig. 2The RMSF plot of docked complex of MolPort-002-530-156, Remdesivir and 6LU7-D1-P-D2 [33], [32], [37].
Fig. 3Average value of radius of gyration (Rg) of high score agents [41], [32], [46].
Fig. 4Mean value of the number of hydrogen bonds between some ligands and corresponding main protease [41], [46].
MM-GBSA/MM-PBSA binding energy analysis of best candidates.
| Ref. | High score lead | Binding energy analysis (MM-GBSA/MM-PBSA) kcal/mol |
|---|---|---|
| Remdesivir | −23.611 | |
| Dexamethasone and Prednisolone complex with the target protein (6LU7-D1-P complex) | −8.7 | |
| 54035018-Mpro | −37.40 | |
| TCM 57,025 | −55.640 | |
| Nelfinavir | −68.943 | |
| MolPort-000–410-348 | −63.34 ± 2.03 | |
| AG-690/11203374–1 AG-690/11203374–2 | −56.54 | |
| Daniquidone | −33.039 | |
| Cefsulodin | −41.3 ± 6.7 | |
| Mpro_Mulberroside E RdRp_Emblicanin A | −33.783 ± 2.224 | |
| Cmp 78 | −60.05 | |
| ZINC00793735 | −6.20 | |
| Withanolide R - main protease | −33.906 | |
| 3CLpro - Lopinavir | −47.2 ± 5.3 |